References
- LabrieFBelangerALuu-TheVGonadotropin-releasing hormone agonists in the treatment of prostate cancerEndocr Rev200526336137915867098
- HarrisWPMostaghelEANelsonPSMontgomeryBAndrogen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNat Clin Pract Urol200962768519198621
- SchroederFHHugossonJRoobolMJERSPC InvestigatorsProstate-cancer mortality at 11 years of follow-upN Engl J Med20123661198199022417251
- LundstromEARenckenRKvan WykJHTriptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III studyClin Drug Investig20092912757765
- AnderssonSORashidkhaniBKarlbergLWolkAJohanssonJEPrevalence of lower urinary tract symptoms in men aged 45–79 years: a population-based study of 40 000 Swedish menBJU Int200494332733115291861
- GuessHABenign prostatic hyperplasia and prostate cancerEpidemiol Rev20012315215811588841
- HamiltonWSharpDSymptomatic diagnosis of prostate cancer in primary care: a structured reviewBr J Gen Pract20045450561762115296564
- LehrerSStoneNNDrollerMJStockRGAssociation between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancerUrol Oncol200272737612474526
- HeynsCFSimoninMPGrosgurinPSchallRPorchetHCSouth African Triptorelin Study GroupComparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancerBJU Int200392322623112887472
- TeillacPHeynsCFKaisaryAVBouchotOBlumbergJPharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancerHorm Res200462525225815499224
- Martinez-PineiroLSchalkenJACabriPMaisonobePde la TailleATriptocare Study GroupEvaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancerBJU Int20131144608616
- PloussardGMongiat-ArtusPTriptorelin in the management of prostate cancerFuture Oncol2013919310223252566
- PeltierAAounFDe RuyterVCabriPVan VelthovenRTriptorelin in the relief of lower urinary tract symptoms in advanced prostate cancer patient: the RESULT studyProstate Cancer2015201597819425694830
- BoschJLHopWCKirkelsWJSchroderFHThe International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volumeBr J Urol19957556226307542132
- GilTAounFCabriPMaisonobePvan VelthovenRA prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancerTher Adv Urol20157311612426161142
- CuiYZongHYanHLiNZhangYDegarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systemic review and meta-analysisUrol Int20149315215924603064
- PetersCAWalshPCThe effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasiaN Engl J Med1987317105996042441256
- PadhaniARMacVicarADGapinskyCJEffects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imagingRadiology2001218236537411161148